WAYLAND, Mass.--(BUSINESS WIRE)--Jan. 21, 1997-- Candela Corporation (NASDAQ: CLZR) today announced that it has received U.S. patent number 5,599,342 for an innovative elongated spot handpiece used for laser treatment of linear lesions such as leg veins, stretch marks, and facial spider veins, as well as tattoos.
The elongated spot handpiece provides physicians with the ability to treat linear lesions and remove tattoos more precisely, with a reduction in temporary discoloration by avoiding unnecessary exposure to surrounding uninvolved tissue.
According to James C. Hsia, Ph.D., Candela's senior vice president of Research and Development, "The handpiece has two key advantages, including limiting the collateral damage to the skin, as well as allowing for the treatment of a larger section of the linear lesion, resulting in a faster and more efficient procedure."
Gerard E. Puorro, Candela's president and chief executive officer, said, "We are delighted to be the only laser company to offer physicians this handpiece. The device is one of several unique products -- including the patent-pending and FDA-cleared Dynamic Cooling Device (DCD) -- which facilitate and enhance the use of our advanced medical, cosmetic laser systems."
The handpiece was introduced to the market in mid-1996 and has been embraced by the medical community. Currently, it can be used with Candela's ScleroPLUS, ScleroLASER, and the SPTL-1b Vascular Lesion Laser.
Candela Corporation develops, manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical problems using lasers, cryosurgery, and other proven technologies. In addition, the company is applying its capabilities and experience with skin care and related problems to develop a network of company-owned skin care centers and spas. Founded near Boston in 1970 as Candela Laser Corporation, Candela markets and services its products in over 40 countries from offices in the United States, Europe, and the Far East. For more information about Candela, visit the company's web site at clzr.com . -0-
This press release includes certain forward-looking statements. Any such statements are subject to risks that could cause the actual results to vary materially, including negative developments relating to unforeseen order cancellations or push-outs, Candela's strategic relationships, the impact of intense competition, and changes in the laser industry.
CONTACT:
Candela
Jane Smith, 508-358-7637 (Ext. 247)
Arthur Dimond, 617-424-8373
Stuart Pearlman, 212-370-4940
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICINE
BW1241 JAN 21,1997 |
